Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.76 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29944207 | 1.00 | HRH4 (0.76) | HRH4HRH3POLBSMN1; SMN2NPC1 | |
| SCHEMBL2350768 | 0.98 | HRH4 (0.78) | HRH4HRH3POLBSMN1; SMN2NPC1 | |
| SCHEMBL602187 | 0.88 | HRH4 (0.74) | HRH4HRH3POLBSMN1; SMN2DRD2 | |
| SCHEMBL22615143 | 0.87 | HRH4 (0.89) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| Benzoxazolinone SCHEMBL3094881 | 0.86 | POLB (0.60) | HRH4HRH3POLBSMN1; SMN2NPC1 | |
| SCHEMBL28469741 | 0.86 | HRH4 (0.74) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL29699763 | 0.86 | HRH4 (1.00) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL2679610 | 0.86 | HRH4 (1.00) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| Potassium Ion SCHEMBL22615122 | 0.85 | HRH4 (0.71) | HRH4HRH3POLBSMN1; SMN2NPC1 | |
| SCHEMBL22615176 | 0.85 | HRH4 (0.74) | HRH4HRH3POLBSMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| CN-101248072-B | 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC | 2013-01-23 | — | — | CN | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8076360-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076360-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2102186-B1 | INDOLES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2102186-B1 | INDOLES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| WO-2006023590-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-07-21 | — | — | US | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
| EP-1328514-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002034718-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2002-05-02 | — | — | WO | disclosed |
| WO-2000037074-A1 | MUTILIN 14-ESTER DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | HRH4 20/4885HRH3 21/4885POLB 3229/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | HRH4 21/4885HRH3 13/4885POLB 2797/4885 |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | HRH4 19/4885HRH3 16/4885POLB 3020/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | HRH4 19/4885HRH3 20/4885POLB 3190/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | HRH4 34/4885HRH3 48/4885POLB 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.